comparemela.com

Latest Breaking News On - Us department of justice resolution - Page 1 : comparemela.com

Indivior Shareholders Approve Resolutions to Proceed with Additional U S Listing

Indivior plc (via Public) / Research Indicates Sustained High Plasma Concentrations of Buprenorphine Reduce Fentanyl-Induced Respiratory Depression in Opioid-Tolerant Participants

Indivior plc (via Public) / Research Indicates Sustained High Plasma Concentrations of Buprenorphine Reduce Fentanyl-Induced Respiratory Depression in Opioid-Tolerant Participants
publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.

Research Indicates Sustained High Plasma Concentrations of Buprenorphine Reduce Fentanyl-Induced Respiratory Depression in Opioid-Tolerant Participants

Research Indicates Sustained High Plasma Concentrations of Buprenorphine Reduce Fentanyl-Induced Respiratory Depression in Opioid-Tolerant Participants

Study Examining Impact of COVID-19 Pandemic on Opioid Use Disorder (OUD) Finds Greater Barriers to Care During Pandemic

Share this article Share this article RICHMOND, Va., April 22, 2021 /PRNewswire/ Indivior PLC (LON: INDV) today announced findings from a qualitative study examining the impact of COVID-19 on opioid use disorder (OUD) management and medication for opioid use disorder (MOUD) access in the U.S. which found that 85% of participants agreed that patients with OUD experienced more barriers to care during the COVID-19 pandemic. 1 Results from the study, entitled Impact of COVID-19 on OUD Management and MOUD Access in the US, were presented at the American Society of Addiction Medicine (ASAM) 2021 virtual meeting. The study was conducted to understand the impact of the COVID-19 pandemic on the management of OUD in the US from both provider and payer perspectives, as well as to gain insight into strategies adopted by healthcare organizations to overcome access barriers to OUD care and MOUD.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.